Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 3 Skin Trial
January 06, 2016 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the...
Paratek Expands Leadership Team
December 03, 2015 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) has expanded its senior leadership team. The company announced today that Raj Padmanabhan has joined as Vice...
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results
November 12, 2015 07:00 ET
|
Paratek Pharmaceuticals
Enrolling Patients in Phase 3 Registration Study of Omadacycline in Community Acquired Bacterial Pneumonia
Granted FDA Fast Track Status for Omadacycline
Advancing Phase 3 Registration...
Paratek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia (CABP)
November 09, 2015 07:30 ET
|
Paratek Pharmaceuticals
Dosing initiated in second of two Phase 3 registration studies for Paratek's omadacycline
Phase 3 program designed to support approval in two indications: acute bacterial skin and skin...
Paratek Pharmaceuticals to Report Third Quarter 2015 Financial Results on November 12, 2015
November 05, 2015 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Receives FDA Fast Track Designation for Omadacycline
November 04, 2015 16:10 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 4, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that the U.S. Food and Drug Administration (FDA) has granted omadacycline Fast Track Designation...
Paratek Expands Leadership Team With Two New Hires
October 01, 2015 07:30 ET
|
Paratek Pharmaceuticals
Regina Paglia joins as Senior Vice President of Human Resources
Stephen Villano, M.D., joins as Vice President of Clinical and Medical Affairs
BOSTON, Oct. 1, 2015 (GLOBE NEWSWIRE) --...
Paratek's Omadacycline, Demonstrates Broad Spectrum Activity in Pathogens Relevant in Skin Infections, Community-acquired Pneumonia and Urinary Tract Infections
September 20, 2015 15:15 ET
|
Paratek Pharmaceuticals
Phase 3 antibiotic demonstrates in vitro activity against Gram-positive bacteria, including community-acquired strains of MRSA, Gram-negatives and atypical pathogens such as...
Paratek Pharmaceuticals, Inc. Announces Participation in Ladenburg Thalmann 2015 Healthcare Conference
September 02, 2015 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Medical Officer, Evan Loh, MD, will participate in the Ladenburg...
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial and Operating Results
August 05, 2015 07:00 ET
|
Paratek Pharmaceuticals
Completed a successful follow-on common stock offering to further strengthen company's financial position
Initiated Phase 3 Registration Study of Omadacycline in Acute Bacterial Skin and Skin...